{
    "clinical_study": {
        "@rank": "114296", 
        "arm_group": {
            "arm_group_label": "Clobex spray", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is to investigate the utility of a technological based rating scale\n      for assessing improvement in plaque psoriasis with Clobex spray treatment."
        }, 
        "brief_title": "Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex\u00ae (Clobetasol Propionate) Spray 0.05%", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Plaque Psoriasis", 
        "condition_browse": {
            "mesh_term": [
                "Erythema Multiforme", 
                "Psoriasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects 18 years of age or older.\n\n          -  Subjects with a board certified dermatologist clinical diagnosis of active moderate\n             to severe psoriasis lesions affecting up to 20% of the body surface area at the\n             baseline visit, and in the opinion of the investigator, is otherwise a good candidate\n             for treatment with clobetasol propionate 0.05% spray.\n\n          -  Subjects with a target lesion of at least 1 cm x 1 cm\n\n          -  Subjects who agree to be photographed at each visit\n\n        Exclusion Criteria:\n\n          -  Subjects with any condition or presentation that may, in the opinion of the\n             investigator, may put the subject at risk, may confound study results, or may\n             interfere with participation in the study.\n\n          -  Subjects with any known allergies to any of the ingredients listed on the test\n             article label or surgical ink.\n\n          -  Subjects who are pregnant or breast-feeding, or who plan to become pregnant or breast\n             feed during the course of the trial.\n\n          -  Subjects that are relatives of the investigator, or are themselves or a relative of\n             any study staff or any Galderma employee.\n\n          -  Subjects who have participated in an investigational study within 30 days of\n             enrollment; participated in biologic investigational studies within 90 days of\n             enrollment, or subjects planning to participate in any other interventional clinical\n             research study while enrolled in this trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01893567", 
            "org_study_id": "GLI.04.SPR.US10243"
        }, 
        "intervention": {
            "arm_group_label": "Clobex spray", 
            "intervention_name": "Clobex Spray", 
            "intervention_type": "Drug", 
            "other_name": "Clobetasol propionate spray"
        }, 
        "intervention_browse": {
            "mesh_term": "Clobetasol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Gratiot", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48059"
                }, 
                "name": "Hamzavi Dermatology"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex\u00ae (Clobetasol Propionate) Spray 0.05%", 
        "overall_official": {
            "affiliation": "Hamzavi Dermatology", 
            "last_name": "Fasahat Hamzavi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Relationship between digital photographs of a target lesion and investigator an subject reported severity scores", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01893567"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Investigator reported effectiveness scores", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Subject reported effectiveness scores", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }
        ], 
        "source": "Galderma Laboratories, L.P.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galderma Laboratories, L.P.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}